Treatment of relapsing–remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial

Preliminary results of a multicenter, randomized study on the effect of natural interferon beta (n-INFN-β) in relapsing-remitting MS are reported. Sixty patients received either no treatment or n-IFN-β) (9 MIU three times a week, subcutaneously). After 6 months, the n-IFN-β-treated group showed a 58% median reduction in the number of active lesions detected on monthly magnetic resonance imaging scans as well as a 38% reduction in the exacerbation rate as compared with the control group. Side-effects were mild and self-limiting. The study continues according to the protocol.

• Publication year

  1995

• Venue

  Multiple Sclerosis

• Publication date

  1995-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458519950101067PMID 9345404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

  1991cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Intrathecal interferon reduces exacerbations of multiple sclerosis.

  1981cited by this paper

• Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia.

  2015cites this paper
• Oral Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis: Systematic Review and Indirect Treatment Comparison

  2011cites this paper
• Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis

  2010cites this paper
• Drug Class Review on Disease-modifying drugs for Multiple Sclerosis

  2007cites this paper
• Diagnóstico y tratamiento de la esclerosis múltiple

  2004cites this paper
• Interferons in Relapsing-Remitting Multiple Sclerosis

  2004cites this paper
• Interferons in relapsing remitting multiple sclerosis: a systematic review.

  2003cites this paper
• Factors modifying the migration of lymphocytes across the blood-brain barrier.

  2001cites this paper
• Natural interferon‐β treatment of relapsing—remitting and secondary‐progressive multiple sclerosis patients. A two‐year study

  1999cites this paper
• Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study.

  1999cites this paper
• Review of the Results of Previous Phase II, Magnetic Resonance Imaging-monitored Clinical Trials

  1999cites this paper
• Interferon beta in the treatment of multiple sclerosis

  1998cites this paper
• Microglial Production of TNF- a Is Induced by Activated T Lymphocytes

  1997cites this paper
• Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.

  1997cites this paper
• Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b.

  1997cites this paper
• Interferon-beta: Structure, differential actions, and medical applications

  1997cites this paper
• Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9

  1996cites this paper
• Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

  1996cites this paper
• Interferon beta treatment in multiple sclerosis: the European clinical trials

  1996cites this paper
• Interferons in relapsing remitting multiple sclerosis : a systematic review

  year unknowncites this paper